Geron Stock (NASDAQ:GERN)
Previous Close
$1.45
52W Range
$1.04 - $2.01
50D Avg
$1.31
200D Avg
$1.40
Market Cap
$910.96M
Avg Vol (3M)
$12.69M
Beta
0.60
Div Yield
-
GERN Company Profile
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Revenues Before Adjustments | $223.11M | $89.42M |
| Sales Returns And Allowance | $-3.85M | $-225.00K |
| Total Gross To Net Adjustments | $-39.49M | $-12.92M |
| Government Rebates | $-2.60M | $-926.00K |
| Chargebacks | $-25.52M | - |
| Product | $183.62M | $76.50M |
| Chargeback And Distributor Service Fees | - | $-11.77M |
Fiscal year ends in Dec 25 | Currency in USD